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Abstract
Introduction. Although surgical endarterectomy remains the treatment of choice for carotid artery stenosis, 
carotid artery stenting (CAS) with use of proximal protection systems (PPS) plays an important role as alternative 
treatment modality, especially in high risk patients.
This study was aimed at the assessment of safety of CAS with use of the PPS and also at identification of risk 
factors associated with this procedure.
Material and methods. This was a post hoc analysis, with 30-day follow-up. We analysed results of 
treatment of 94 patients who underwent 97 CAS with PPS, 47 such procedures in asymptomatic, and 50 in 
symptomatic individuals.
Results. There were 0 strokes during 30-day follow-up. Transient ischaemic attacks occurred in 2 patients (2%) 
in symptomatic group. Risk factors of these adverse events comprised: tortuosity of the managed artery, chronic 
obstructive pulmonary disease, long lesion of the internal carotid artery and history of myocardial infarction.
Conclusions. CAS with the use of PPS seems to be a relatively very safe procedure in high risk patients.
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Introduction
Carotid artery angioplasty with stenting (CAS) is 
increasingly playing a role as alternative for surgical 
endarterectomy (CEA) in high risk patients, and also 
in those patients who present with other, non-stenotic 
lesions of the carotid arteries [1–4]. Most of published 
papers on CAS deal with distal protection systems 
(DPS) [5–9]. Still, it is believed that proximal protection 
systems (PPS) in terms of their safety and efficacy have 
potential advantage over distal ones, yet evidence of 
such superiority remains to be documented [10–13]. 
This post hoc survey, with 30-day follow-up, was 
aimed at the assessment of safety and efficacy of CAS 
with the use of PPS for the treatment of internal carotid 
artery (ICA) stenosis and at identification of risk factors 
associated with this procedure.
Material and methods
We analysed results of the treatment with the use of 
PPS in 94 consecutive patients (34 women and 60 men) 
who were managed by our team at departments of 
vascular surgery from March 2011 to December 2015. 
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Table 1. Demographic and clinical characteristics of the patients; number of patients: N = 94
Patients’ characteristics N %
Age ± SD 69.5 (± 8.05)
Patients older than 80 year 6 5
Male/female ratio 60/34 63/37
Asymptomatic patients 42 42
Risk factors
Stable coronary heart disease 33 35
Arterial hypertension 86 91
Diabetes mellitus type 2 28 30
Dislipidemia 56 60
Cigarette smoking 24 26
Renal impairment 6 6
Peripheral artery disease 6 6
History of percutaneous coronary angioplasty 9 10
History of coronary artery bypass graft surgery 2 2
History of cancer 0 0
History of myocardial infarction 20 21
Symptomatic carotid artery stenosis 55 56
History of transient ischemic attack 26 28
History of stroke 29 31
Bilateral stenosis of the internal carotid artery 33 35
Occlusion of the internal carotid artery 5 5
Stenosis of the vertebral artery 4 4
Table 2. Risks factors in asymptomatic vs. symptomatic patients 
Risk factor Asymptomatic patients  
(47 procedures)
Symptomatic patients  
(50 procedures)
p value
Mean age (± SD) 68.4 ± 8.7 70.7 ± 7.19 NS
Patients aged > 80 years 2 4 NS
Patients aged < 60 years 7 4 NS
Male patients 27 34 NS
Stable coronary heart disease 19 14 < 0.05
Congestive heart failure 3 5 NS
Cigarette smoking 13 11 NS
Diabetes mellitus type 2 9 19 < 0.05
Arterial hypertension 36 50 NS
Dislipidemia 27 29 NS
Renal impairment 3 3 NS
Chronic obstructive pulmonary disease 2 3 NS
Peripheral arterial disease 3 3 NS
History of myocardial infarction 8 12 NS
History of percutaneous coronary angioplasty 3 6 NS
History of coronary artery bypass graft surgery 1 1 NS
Aortic or mitral valve disease 0 0 NS
Contralateral stenosis of the internal carotid artery 14 19 0.06
Occlusion of the internal carotid artery 2 3 NS
Stenosis of the vertebral artery 4 1 NS
NS — difference statistically not significant
Patients were aged 69 ± 8.1 years, 6 patients (5%) 
were aged more than 80 years. A total of 97 endo-
vascular treatments with stent implantation have been 
performed, 47 such procedures in asymptomatic pa-
tients, and 50 stentings in symptomatic patients. Some 
patients underwent endovascular treatment more 
than once. A demographic and clinical characteristic 
of patients, including potential risk factors, is given in 
Table 1, and comparison between asymptomatic and 
symptomatic patients regarding these risk factors 
is presented in Table 2. Localisation of the lesions 
managed with stent implantation is given in Table 3. 
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Flow Reversal System (Gore & Associates, Inc., Flagstaff, 
AZ, USA). The first system protects the brain against 
embolisation thanks to stopped flow in the ICA, which 
occurs after the balloons of this system are expanded in 
the common and external carotid arteries (Fig. 1A). In 
the case of the Gore Flow system, there is a flow rever-
sal in the ICA, which results from temporary shunting 
from the ICA to the femoral vein through catheters and 
filter of this device (Fig. 1B). Mean time of closure of 
the common carotid artery was 422 s (± 178 s); the 
shortest closure time was 150 s. Characteristics of the 
types of PPS, stents utilised in our patients and presence 
of embolic material secured by protection systems are 
given in Table 4. 
Standard preprocedural management of patients 
comprised multidisciplinary assessment, including 
neurological, vascular and cardiologic consultations. 
Potential risks and benefits associated with the planned 
procedure were discussed with the patients, and all 
patients gave their written informed consent. Neuro-
logical assessment was performed at least before the 
procedure and on the first postprocedural day. Sono-
graphic follow-up of the treated arteries was performed 
on the day of procedure, and then after 1 and 6 months.
All patients completed the 30-day follow-up, which 
was primarily aimed at the assessment of safety of 
these endovascular procedures. Patients were advised 
to report any neurological events that occurred during 
this period. Neurological symptoms were categorized 
Table 3. Location of the lesions treated (N = 97)
Artery N %
Left internal carotid artery 48 49
Right internal carotid artery 49 51
Left vertebral artery 4 4
Right vertebral artery 1 1
Figure 1A. Scheme of Mo.Ma system — blockage flow in ICA during inflation of balloon in CCA and ECA; B. Scheme of Gore Flow 
Reversal System — there is a flow reversal in the ICA, which results from temporary shunting from the ICA to the femoral vein through 
catheters and filter of this device during inflation of balloon in ECA and CCA. CCA — common carotid artery; ECA — external carotid 
artery; ICA — internal carotid artery
Inclusion criteria for endovascular angioplasty with 
stent implantation comprised: more than 65% stenosis 
of the ICA in symptomatic patients and more than 80% 
stenosis of the ICA in asymptomatic patients. Main 
indication for the use of PSP instead of another type of 
protection included: presence of unstable symptomatic 
lesions, critically narrowed ICA, tortuosity of the artery, 
presence of thrombi in the lesion, technical problems 
with the use of a DPS.
Exclusion criteria for stenting procedure comprised: 
highly calcified lesions, no adequate vascular access, 
contraindications for antiplatelet therapy and a lack of 
patient’s consent. Symptomatic patients were managed 
at least 5 days after neurologic event, preferentially on 
the 7th–10th day, depending on the findings of MRI of the 
brain and appearance of cerebral lesions revealed by 
this test; this was in line with recommendations coming 
from published studies [10, 12].
Two types of PPS were utilised: the Mo.Ma 
(Medtronic, Minneapolis, MN, USA) and the Gore 
A B
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as follows: transient ischaemic attack, which was de-
fined as an acute neurological deficit resulting from 
focal temporary cerebral or retinal ischaemia that 
lasted less than 24 hours; stroke, which was defined 
as a new cerebrovascular event of ischaemic or haem-
orrhagic aetiology resulting in cerebral infarction and 
neurological deficit. Strokes were further classified as: 
minor — with neurological deficits lasting less than 
30 days, or lasting longer than 30 days but presenting 
with small deficit (National Institute of Health Stroke 
Scale up to 4 points); major — with neurological defi-
cits lasting longer than 30 days; and fatal — a stroke 
(ischaemic or haemorrhagic) resulting in death. 
The primary endpoint was the proportion of pa-
tients who had stroke or stroke-related death. We 
included all types of strokes, both ipsi- and contralateral, 
as well as minor, major and fatal strokes. 
The secondary endpoint was the proportion of pa-
tients who had myocardial infarction (both STEMI and 
non-STEMI events) or a death that was not caused by 
stroke. In addition to demographic and clinical data of 
the patients, we analysed angiographic characteristics, 
such as presence of coexisting lesions in other arteries 
supplying the brain, including intracranial stenoses. 
Also, we assessed endovascular technique used (type 
of protection, type of stent, duration of the procedure, 
duration of occlusion of an artery, etc.). 
Statistical analysis
Continuous variables were expressed as means 
± standard deviation; categorical variables were ex-
pressed as percentages. Analysis of normality was 
performed with the Kolmogorov-Smirnov test. Com-
parison of categorical variables between the groups was 
performed using the chi-square test. Comparisons of 
continuous variables between the two groups were per-
formed using the independent sample t-test. Multivari-
ate, stepwise backward conditional logistic regression 
analysis was used to determine independent predictors 
of successful intervention. All significant parameters in 
the univariate analysis were selected in the multivariate 
model. The significance of the two-tailed p was set at 
p < 0.05. Statistical analysis was performed using the 
SPSS software (Statistical Package for the Social Scienc-
es (version 23.0, SPSS Inc., Chicago, IL, USA).
Results
Complications associated with the treatment are 
presented in Table 5. There was neither a fatality nor 
a stroke during 30-day follow-up. Transient ischaemic 
Table 5. Complications in asymptomatic vs. symptomatic 
patients
Complications during 
30-day follow up
Asymptoma-
tic patients  
(47 proce-
dures)
Symptoma-
tic patients  
(50 proce-
dures)
p value
Stroke 0 0 NS
Transient ischemic 
attack
0 2 NS
Hyperperfusion syn-
drome
1 0 NS
Other serious neuro-
logical events
0 0 NS
Myocardial infarction 0 0 NS
All fatalities during 
30-day follow up 
0 0 NS
NS — difference statistically not significant
Table 4. Characteristics of protection systems and stents utilized in 408 procedures in asymptomatic vs. symptomatic patients
Asymptomatic patients  
(47 procedures)
Symptomatic patients  
(50 procedures)
p value
Protection systems
Proximal protection systems 40 57 NS
Mo.Ma (Medtronic, Minneapolis, MN, USA) 36 50 NS
Gore Flow Reversal System  (Gore & Associates, Inc., Flagstaff, 
AZ, USA) 
4 7 NS
Stents
Precise (Cordis, Fremont, CA, USA) 8 21 0.05
Carotid Wallstent (Boston Scientific, Natick, MA, USA) 16 23 0.05
Cristallo Ideale (Medtronic, Minneapolis, MN, USA) 16 13 NS
Close-cell design stents 32 36 NS
Open-cell stents 8 21 0.05
Macroscopically visible embolic material in protection system
Single plaque or thrombus 16 25 0.05
A little of debris 0 3 NS
A lot of debris 3 3 NS
NS — difference statistically not significant
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attacks (TIA), which resolved within 6 hours, occurred 
in 2 patients (2.1%). These patients had a history of 
previous TIAs. There was one case (1.0%) of post-
procedural hyperperfusion syndrome. This patient, who 
presented with bilateral critical stenosis of the ICAs, 
developed this syndrome 10 hours after successful 
revascularization of the left ICA. Conservative manage-
ment resulted in complete resolution of neurological 
symptoms. After one month this patient underwent 
successful revascularization of the contralateral ICA. 
Five patients (5.1%) developed neurological symptoms 
after introduction of the PPS, majority of these patients 
presented with contralateral carotid lesions. Still, there 
were no clinical consequences associated with this in-
tolerance. Complication rates did not differ significantly 
between symptomatic and asymptomatic patients.
During or after the procedure 3 asymptomatic 
(6.4%) and 2 symptomatic patients (4.0%) developed 
hypotension, which required an intravenous adminis-
tration of dopamine, yet did not result in further clinical 
sequelae. Logistic multivariate analysis revealed several 
risk factors predisposing for peri- and postprocedural 
neurological complications, namely: TIA or intolerance 
of the protection system. These comprised: tortuosity 
of the managed artery, presence of long lesions in the 
internal carotid arteries, a history of chronic obstructive 
pulmonary disease or myocardial infarction. Details are 
given in Table 6. 
Discussion
Incidence of major adverse events in our material 
(0%) was much lower than recommended in the guide-
lines (3% for asymptomatic and 6% for symptomatic 
patients). Still, there are some limitations of our study. 
Firstly, it was a retrospective analysis and patients were 
not randomly allocated into PPS or DPS arms, thus 
a potential selection bias could occur. The same applies to 
the selection of stents, which were tailored according to 
the characteristics and anatomy of lesions. Also, this sur-
vey analysed adverse events during a 30-day follow-up, 
when perhaps a longer observation will be justified. 
In our patients neurological adverse events (only: TIA 
and intolerance of protection system, since there were 
no strokes) were associated with several risk factors: 
tortuosity of the managed artery, long lesions in the 
ICA, history of chronic obstructive pulmonary disease 
and history of myocardial infarction. Other researchers 
found that complications were associated with bilateral 
carotid disease, long lesions, advanced patient’s age 
and a history of myocardial infarction [10, 11, 13–16]. 
Data revealed by large-scale registries on endovascular 
carotid interventions suggest that because of a risk of 
cerebral embolisation, the use of protection system 
during CAS is warranted [10, 11, 17, 18]. Indeed, in 
our patients very often there was quite a lot of embolic 
material filtered by protection system (Table 4). 
For the time being CAS procedures are primarily 
performed with the use of a (DPS) [5–9]. Prevalence 
of ischaemic cerebral events during 30-day follow-up 
reported by randomised trials, with different types of 
DSP utilised, was at the level of 4% in asymptomatic 
patients, and even as high as 10% in symptomatic in-
dividuals [5–9]. By contrast, open-label studies when 
also a proximal protection has been applied (such 
a system was used in approximately 30% of procedures) 
reported much lower rates of adverse events: 0.9–2.4% 
of death or stroke [10–13]. There is a growing body 
of evidence supporting the use of PPS during CAS. 
Regarding the Mo.Ma system, there are some already 
published studies [12, 19, 20]. In the randomized mul-
ticentre ARMOUR study, which evaluated a group of 
222 patients (15% of them were symptomatic, 29% 
were older than 80 years; occlusion or stenosis of the 
contralateral artery constituted an exclusion criterion 
for the use of PPS) the composite complication rate 
(comprising: stroke, death and myocardial infarction) 
was 2.7%, and stroke rate during 30 days was 0.9% [12]. 
In the study published by Stabile et al. the Mo.Ma 
system was used in 1,300 patients. The composite 
complication rate (comprising: stroke and death) at 
30-day follow-up was 1.4% (3% in symptomatic 
patients and 0.9% in asymptomatic ones). It was not 
increased in elderly patients. Low operator experience 
(less than 100 procedures performed) was associated 
with a higher risk of adverse events [19]. In 2014 Khripun 
et al. published the results of an open-label study with 
the use of the Mo.Ma system. Incidence of complications 
during 30-day follow-up in this survey was 0.6% [20].
Efficacy and safety of the Gore Flow Reversal System 
have been evaluated in the multicentre prospective, 
nonrandomized EMPiRE study [21]. In this study 245 
patients have been studied, including 30% symptomatic 
and 16% older than 80 years. In this study contralateral 
stenosis or occlusion was not an exclusion criterion 
(actually, 10.5% of patients enrolled presented with 
Table 6. Risk factors associated with postprocedural compli-
cations (TIA, intolerance of protection system) revealed by 
logistic multivariate analysis
All patients (97 procedures)
Risk factor Hazard ratio p value
Tortuosity of the managed artery 12.15 0.002
Chronic obstructive pulmonary disease 7.36 0.007
Long lesion of the internal carotid 
artery 7.36 0.007
History of myocardial infarction 4.42 0.03
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an occlusion of the contralateral ICA). Composite 
complication rate (including: stroke, death, myocardial 
infarction or TIA) during 30-day follow-up was 4.5%. 
Composite complication rate comprising only stroke 
and death was 2.9% (still, not a single patient in this 
study developed major stroke). The death/stroke 
rates in this study in the symptomatic, asymptomatic, 
and patients older than 80 years were 2.6%, 3%, and 
2.6%, respectively [21]. Another study on the use of 
the Gore Flow Reversal System, which was published 
in 2012 by Nikas et al., revealed complication rate 
(comprising: stroke, death and myocardial infarction) 
at the level of 1.6% [22].
Similarly, clinical benefit associated with the use 
of a PPS has been demonstrated by cerebral diffusion 
MR studies. Bijuklic et al., who compared distal and 
proximal protection systems studying postprocedural 
cerebral lesions by means of diffusion MR imaging, found 
that there were significantly fewer new lesions (45.2% 
vs. 87.1%; p = 0.001) if the PPS were used [23]. Mon-
toresi et al. [24] demonstrated that there were fewer 
periprocedural embolic events with the use of the 
Mo.Ma system if compared to a DPS: the FilterWire. 
Meta-analysis by Bersin et al. [25], which was published 
in 2012 and discussed results of CAS with the use of PPS 
in 2397 patients, reported 1.71% stroke rate during 
30-day follow-up and 2.6% incidence of stroke, death 
or myocardial infarction. In this meta-analysis diabetes 
mellitus and advanced patient’s age were found to be 
associated with increased risk of adverse events.
All the above-citied data are in line with our results. 
There were neither fatalities nor strokes in our patients, 
and the only major adverse events comprised two TIAs 
that completely resolved within few hours, without 
further neurological sequelae. Although an introduction 
of PPS into the ICA can be technically challenging and 
there were many patients with contralateral carotid 
disease (about 40% of our patients presented with 
significant, at least 70%, stenosis of contralateral ICA, 
and about 5% of patients had completely occluded 
contralateral artery), only 5.1% of patients developed 
neurological symptoms after introduction of PPS and 
there were no clinical consequences related to this in-
tolerance. By contrast, in the AROMOUR study, which 
did not enrol patients with significant contralateral 
carotid lesions, there was an intolerance of protection 
system in 13.8% of patients and 0.9% stroke rate [12]. 
Low incidence of neurological adverse events associ-
ated with the use of PPS by our team can partially be 
explained by some modifications of endovascular tech-
nique used. In each patient we tried to postpone the clo-
sure of the common carotid artery until the guidewire 
and stent were introduced into the distal part of the 
system. In selected cases (there were 2 such patients) 
we utilised both proximal and distal protections. Such 
a dual protection has already been shown to be safe 
and effective [22, 26]. Also, we applied lesion-tailored 
stents: preferentially closed-cell stents, but in selected 
patients who presented with tortuous arteries we 
implanted stents with an open-cell design (such as the 
Precise stent/Cordis, Fremont, CA, USA). Although we 
did not observe different clinical outcomes in patients 
managed with closed- and open-cell stents, other 
researchers revealed better results after implantation 
of closed-cell stents [27]. Still, for technical reasons, 
such stents cannot be used in every case. Recently, 
a new generation of carotid stents has been marketed; 
these stents combine small area of the cells with flexi-
bility characteristic for open-cell devices. Perhaps, such 
stents, which appear to be an interesting alternative for 
currently utilised ones, will further improve results of 
carotid stenting [27, 28]. 
Whilst our study is not definitive and therefore 
cannot guide the treatment, nonetheless we have 
found that in patients presenting with tortuosity of the 
managed artery, presence of long lesions in the inter-
nal carotid arteries, a history of chronic obstructive 
pulmonary disease or myocardial infarction, periproce-
dural adverse events were more likely that in patients 
without these risk factors. Thus, perhaps in individuals 
presenting with these comorbidities an alternative 
treatment modality should be considered, either sur-
gical endarterectomy, carotid stenting with the use of 
distal protection, or pharmacological treatment.
Conclusions
We can conclude that CAS with the use of a PPS is 
a relatively safe endovascular procedure, with a po-
tential benefit over DPS. We suggest that proximal 
protection devices should be used whenever technically 
feasible, still in patients presenting with risk factors of 
periprocedural adverse event, such as tortuosity of 
the managed artery, presence of long lesions in the 
internal carotid arteries, a history of chronic obstructive 
pulmonary disease or myocardial infarction, an alterna-
tive treatment modality should be considered. Future 
strategy treatment for carotid artery stenosis should 
be based on an individual approach. 
References
1. Endarterectomy for asymptomatic carotid artery stenosis. 
Executive Committee for the Asymptomatic Carotid Athero-
sclerosis Study. JAMA. 1995; 273(18): 1421–1428, indexed in 
Pubmed: 7723155.
2. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carot-
id endarterectomy in patients with symptomatic moderate or 
severe stenosis. North American Symptomatic Carotid Endar-
7www.journals.viamedica.pl/acta_angiologica
Pawel Latacz et al., Safety and efficacy of endovascular treatment for carotid artery stenoses using PPS
terectomy Trial Collaborators. N Engl J Med. 1998; 339(20): 
1415–1425, doi: 10.1056/NEJM199811123392002, indexed in 
Pubmed: 9811916.
3. North American Symptomatic Carotid Endarterectomy Tri-
al Collaborators. Beneficial effect of carotid endarterecto-
my in symptomatic patients with high-grade carotid ste-
nosis. N Engl J Med. 1991; 325(7): 445–453, doi:  10.1056/
NEJM199108153250701, indexed in Pubmed: 1852179.
4. Randomised trial of endarterectomy for recently symptomatic 
carotid stenosis: final results of the MRC European Carotid 
Surgery Trial (ECST). Lancet. 1998; 351(9113): 1379–1387, 
indexed in Pubmed: 9593407.
5. Hobson RW, Howard VJ, Roubin GS, et al. CREST Investigators. 
Carotid artery stenting is associated with increased complica-
tions in octogenarians: 30-day stroke and death rates in the 
CREST lead-in phase. J Vasc Surg. 2004; 40(6): 1106–1111, 
doi: 10.1016/j.jvs.2004.10.022, indexed in Pubmed: 15622363.
6. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stent-
ing in patients with symptomatic severe carotid stenosis. N Engl 
J Med. 2006; 355(16): 1660–1671, doi: 10.1056/nejmoa061752.
7. Wimmer NJ, Yeh RW, Cutlip DE, et al. Risk prediction for 
adverse events after carotid artery stenting in higher surgical 
risk patients. Stroke. 2012; 43(12): 3218–3224, doi: 10.1161/
STROKEAHA.112.673194, indexed in Pubmed: 23127975.
8. Bangalore S, Kumar S, Wetterslev J, et al. Carotid artery stenting 
vs carotid endarterectomy: meta-analysis and diversity-adjusted 
trial sequential analysis of randomized trials. Arch Neurol. 2011; 
68(2): 172–184, doi: 10.1001/archneurol.2010.262, indexed in 
Pubmed: 20937941.
9. Massop D, Dave R, Metzger C, et al. SAPPHIRE Worldwide 
Investigators. Stenting and angioplasty with protection in 
patients at high-risk for endarterectomy: SAPPHIRE World-
wide Registry first 2,001 patients. Catheter Cardiovasc Interv. 
2009; 73(2): 129–136, doi: 10.1002/ccd.21844, indexed in Pu-
bmed: 18924164.
10. Cremonesi A, Gieowarsingh S, Spagnolo B, et al. Safety, efficacy 
and long-term durability of endovascular therapy for carotid ar-
tery disease: the tailored-Carotid Artery Stenting Experience of 
a single high-volume centre (tailored-CASE Registry). EuroInt-
ervention. 2009; 5(5): 589–598, indexed in Pubmed: 20142180.
11. Pieniazek P, Musialek P, Kablak-Ziembicka A, et al. Carotid ar-
tery stenting with patient- and lesion-tailored selection of the 
neuroprotection system and stent type: early and 5-year results 
from a prospective academic registry of 535 consecutive proce-
dures (TARGET-CAS). J Endovasc Ther. 2008; 15(3): 249–262, 
doi: 10.1583/07-2264.1, indexed in Pubmed: 18540694.
12. Ansel GM, Hopkins LN, Jaff MR, et al. Investigators for the AR-
MOUR Pivotal Trial. Safety and effectiveness of the INVATEC 
MO.MA proximal cerebral protection device during carotid 
artery stenting: results from the ARMOUR pivotal trial. Catheter 
Cardiovasc Interv. 2010; 76(1): 1–8, doi:  10.1002/ccd.22439, 
indexed in Pubmed: 20222019.
13. Pieniążek P, Tekieli L, Musiałek P, et al. Carotid artery stenting 
according to the tailored-CAS algorithm is associated with a low 
complication rate at 30 days: data from the TARGET-CAS study. 
Kardiol Pol. 2012; 70(4): 378–386.
14. White RA, Sicard GA, Zwolak RM, et al. SVS Outcomes Com-
mittee. Society of vascular surgery vascular registry compari-
son of carotid artery stenting outcomes for atherosclerotic vs 
nonatherosclerotic carotid artery disease. J Vasc Surg. 2010; 
51(5): 1116–1123, doi:  10.1016/j.jvs.2009.11.082, indexed in 
Pubmed: 20347551.
15. Doig D, Turner EL, Dobson J, et al. Predictors of stroke, my-
ocardial infarction or death within 30 days of carotid artery 
stenting: results from the International Carotid Stenting Study. 
Eur J Vasc Endovasc Surg. 2016; 51(3): 327–334, doi: 10.1016/j.
ejvs.2015.08.013.
16. Khan M, Qureshi AI. Factors associated with increased rates of 
post-procedural stroke or death following carotid artery stent 
placement: a systematic review. J Vasc Interv Neurol. 2014; 
7(1): 11–20.
17. Pandey AS, Koebbe CJ, Liebman K, et al. Low incidence of 
symptomatic strokes after carotid stenting without embolization 
protection devices for extracranial carotid stenosis: a single-in-
stitution retrospective review. Neurosurgery. 2008; 63(5): 867–
72; discussion 872, doi:  10.1227/01.NEU.0000327886.32379.
D0, indexed in Pubmed: 19005376.
18. Reimers B, Schlüter M, Castriota F, et al. Routine use of cer-
ebral protection during carotid artery stenting: results of 
a multicenter registry of 753 patients. Am J Med. 2004; 116(4): 
217–222, doi: 10.1016/j.amjmed.2003.09.043, indexed in Pub-
med: 14969648.
19. Stabile E, Salemme L, Sorropago G, et al. Proximal endovas-
cular occlusion for carotid artery stenting: results from a pro-
spective registry of 1,300 patients. J Am Coll Cardiol. 2010; 
55(16): 1661–1667, doi: 10.1016/j.jacc.2009.11.079, indexed in 
Pubmed: 20394868.
20. Diuzhikov AA, Khripun AV, Malevannyĭ MV, et al. Immediate and 
remote results of using carotid endarterectomy and stenting of 
internal carotid arteries. Angiol Sosud Khir. 2013; 19(2): 102–110.
21. Clair DG, Hopkins LN, Mehta M, et al. EMPiRE Clinical Study 
Investigators. Neuroprotection during carotid artery stenting 
using the GORE flow reversal system: 30-day outcomes in 
the EMPiRE Clinical Study. Catheter Cardiovasc Interv. 2011; 
77(3): 420–429, doi:  10.1002/ccd.22789, indexed in Pu-
bmed: 20853365.
22. Nikas D, Reith W, Schmidt A, et al. Prospective, multicenter 
European study of the GORE flow reversal system for providing 
neuroprotection during carotid artery stenting. Catheter Cardi-
ovasc Interv. 2012; 80(7): 1060–1068, doi: 10.1002/ccd.24402, 
indexed in Pubmed: 22644906.
23. Bijuklic K, Wandler A, Hazizi F, et al. The PROFI study (Preven-
tion of Cerebral Embolization by Proximal Balloon Occlusion 
Compared to Filter Protection During Carotid Artery Stent-
ing): a prospective randomized trial. J Am Coll Cardiol. 2012; 
59(15): 1383–1389, doi: 10.1016/j.jacc.2011.11.035, indexed in 
Pubmed: 22284330.
24. Montorsi P, Caputi L, Galli S, et al. Microembolization during ca-
rotid artery stenting in patients with high-risk, lipid-rich plaque. 
A randomized trial of proximal versus distal cerebral protection. 
J Am Coll Cardiol. 2011; 58(16): 1656–1663, doi:  10.1016/j.
jacc.2011.07.015, indexed in Pubmed: 21982309.
25. Bersin RM, Stabile E, Ansel GM, et al. A meta-analysis of proxi-
mal occlusion device outcomes in carotid artery stenting. Cath-
eter Cardiovasc Interv. 2012; 80(7): 1072–1078, doi: 10.1002/
ccd.24433, indexed in Pubmed: 22454248.
8Acta Angiol, 2017, Vol. 23, No. 1
www.journals.viamedica.pl/acta_angiologica
26. Latacz P, Ochała A, Janas P, et al. Composed angioplasty of the 
multilevel right common and internal carotid artery stenoses 
with implantation stents with used of proximal and distal pro-
tection system. Kardiol Pol. 2012; 70(1): 88–90.
27. Kouvelos GN, Patelis N, Antoniou GA, et al. Meta-ana-
lysis of the Effect of Stent Design on 30-Day Outcome Af-
ter Carotid Artery Stenting. J Endovasc Ther. 2015; 22(5): 
789–797, doi:  10.1177/1526602815598753, indexed in Pub-
med: 26232399.
28. Setacci C, Speziale F, De Donato G, et al. IRON-Guard Study 
Group. Physician-initiated prospective Italian Registry of ca-
rotid stenting with the C-Guard mesh-stent: the IRON-Guard 
registry. Rationale and design. J Cardiovasc Surg (Torino). 2015; 
56(5): 787–791, indexed in Pubmed: 25996843.
29. Kajihara Y, Sakamoto S, Kiura Y, et al. Comparison of dual 
protection and distal filter protection as a distal embolic pro-
tection method during carotid artery stenting: a single-center 
carotid artery stenting experience. Neurosurg Rev. 2015; 38(4): 
671–676, doi:  10.1007/s10143-015-0639-x, indexed in Pu-
bmed: 25953614.
30. Hopf-Jensen S, Marques L, Preiß M, et al. Initial clini-
cal experience with the micromesh Roadsaver carotid 
artery stent for the treatment of patients with sympto-
matic carotid artery disease. J Endovasc Ther. 2015; 22(2): 
220–225, doi:  10.1177/1526602815576337, indexed in Pu-
bmed: 25809366.
31. Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the 
Stent-Protected Angioplasty versus Carotid Endarterectomy 
(SPACE) study to treat symptomatic stenoses at 2 years: a mul-
tinational, prospective, randomised trial. Lancet Neurol. 2008; 
7(10): 893–902, doi: 10.1016/S1474-4422(08)70196-0, indexed 
in Pubmed: 18774746.
32. Ielasi A, Latib A, Godino C, et al. Clinical outcomes following 
protected carotid artery stenting in symptomatic and asymp-
tomatic patients. J Endovasc Ther. 2010; 17(3): 298–307, 
doi: 10.1583/09-2997.1.
